Retinoic acid receptor β2 (RARβ2): Nonivasive biomarker for distinguishing malignant versus benign prostate lesions from bodily fluids

Chirurgia (Romania)

Volumn 109, Issue 6, 2012, Pages 780-784

  Dumache, R ^a   Puiu, M ^b   Minciu, R ^b   Bardan, R ^b   David, D ^a   Tudor, A ^b   Bumbacila B ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b University of Medicine and Pharmacy Victor Babea   (Romania)

Author keywords

Benign prostatic hyperplasia (BPH); Prostate cancer (PCa); Quantitative methylation specific polymerase chain reaction (QMSP); Retinoic acid receptor 2 (RAR 2)

Indexed keywords

DNA; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR, BETA2, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ALGORITHM; ARTICLE; BLOOD; CANCER STAGING; COMPARATIVE STUDY; DNA METHYLATION; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ALGORITHMS; DNA METHYLATION; DNA, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84874088138     PISSN: 12219118     EISSN: 1842368X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2009.
2. Kaiser J. Medicine. Cancer's circulation problem. Science. 2010; 327(5969):1072-4.
3. Sunami E, Vu AT, Nguyen SL, Hoon DS. Analysis of methylated circulating DNA in cancer patients' blood. Methods Mol Biol. 2009;507:349-56.
4. Fleishhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta. 2007;1775(1):181-232. Epub 2006 Oct 7.
5. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RARb2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002;62(9): 2455-61.
6. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer- Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8(2):514-9.
7. Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L. The use of receiver operating characteristic curves in biomedical informatics. J Biomed Inform. 2005;38(5):404-15. Epub 2005 Apr 2.
8. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007; 128(4):683-92.
9. Van Vlodrop IJ, Niessen HE, Derks Svan Vlodrop IJ, Niessen HE, Derks S, et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res. 2011;17(13):4225-31. Epub 2011 May 10.
10. Parekh D.J, Ankerest D.P, Troyer D, Srivastava S, Thompson I.M. Biomarkers for prostate cancer detection. J Urol. 2007;178(6): 2252-9. Epub 2007 Oct 22.
11. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, et al. Quantitative RARb2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res. 2004;10(12 Pt 1):4010-4.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-69.
13. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res. 2007;13(14):4035-41.
14. Geavlete B, Mulaescu R, Moldoveanu C, Stanescu F, Jecu M, Geavlete P. Innovative technique in large benign prostatic hyperplasia - enucleation by plasma vaporization. Chirurgia (Bucur). 2012;107(1):89-94. Romanian
15. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl. 2010;12(5):639-57. Epub 2010 Aug 16.
16. Nastase A, Paslaru L, Niculescu AM, Ionescu M, Dumitraşcu T, Herlea V, et al. Prognostic and predictive potential molecular biomarkers in colon cancer. Chirurgia (Bucur). 2011;106(2):177-85